Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cory Pham

Orthopaedic Surgery Modesto, CA Medical Doctor

NPI 1811351729 CMS profile 7229321

1409 E Briggsmore Ave, Modesto, CA 95355

Open in the dashboard

General payments

$10,161

51 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cory Pham of Modesto, CA is reported in the CMS Open Payments database as having received $10,161 across 51 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $546 10
2024 General $223 6
2023 General $1,356 16
2022 General $3,353 13
2020 General $3,481 4
2019 General $1,201 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cory Pham
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Cory Pham were reported at $546. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Cory Pham Orthopaedic Surgery median Middle half National median
2019 $1,201 $644 $140–$2,844 $163
2020 $3,481 $312 $75–$1,860 $114
2021 $0 $520 $117–$2,495 $132
2022 $3,353 $598 $128–$2,731 $149
2023 $1,356 $461 $128–$2,264 $160
2024 $223 $497 $134–$2,475 $164
2025 $546 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Evolution Surgical, Inc $4,683 6 payments
  2. Saxum Surgical, Inc. $1,259 3 payments
  3. Empire Medical, Inc $1,213 2 payments
  4. Stryker Corporation $936 8 payments
  5. Arthrex, Inc. $884 6 payments
  6. AxoGen $730 13 payments
  7. Globus Medical, Inc. $168 5 payments
  8. TriMed, Inc. $128 1 payment
  9. DePuy Synthes Sales Inc. $55 2 payments
  10. Cornerstone Medical Associates, Inc. $51 3 payments
  11. Other $54 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $6,981 5 payments
  2. Food and Beverage $1,783 39 payments
  3. Travel and Lodging $1,397 7 payments
Products named General payments · program years 2019–2025
  1. MAKO $819 6 payments
  2. AXOGUARD HA+ NERVE PROTECTOR Neurology $400 3 payments
  3. AXOGUARD Neurology $368 2 payments
  4. AXOGUARD Neurology $368 2 payments
  5. AXOGUARD NERVE CAP Neurology $368 2 payments
  6. Avance Nerve Graft $236 6 payments
  7. AxoGuard Nerve Connector $187 5 payments
  8. AXOGUARD NERVE PROTECTOR $187 5 payments
  9. Axoguard HA+ Nerve Protector Neurology $187 5 payments
  10. AXOGUARD NERVE CAP Neurology $187 5 payments
  11. Other $483 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Orthopedic Surgery: 203

Drug cost

$98

Median for Orthopedic Surgery: $1,433

Branded share of claims

100%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $98

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$119,501

Of which drugs: $842

Medicare patients

362

Average age 73

Services billed

1,308

239 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 70%
Diabetes 38%
Chronic kidney disease 29%
Ischemic heart disease 25%
Depression 22%
COPD 19%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 78 152 $816
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 13 56 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

51 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record